BofA Securities upgraded Integer Holdings Corporation (NYSE:ITGR), citing the anticipated growth in pulsed field ablation (PFA) for treating atrial fibrillation.  Integer is one of the largest medical device outsourcing manufacturers, serving the cardiac rhythm management, neuromodulation, vascular, portable medical, and orthopedics markets. The analyst expects the PFA sales to surge from $100 million-200 million in 2023 to over $2 billion in 2025.  Integer supplies key components for major PFA devices by Boston Scientific Corporation (NYSE:BSX), Medtronic Plc (NYSE:MDT), and Johnson & Johnson (NYSE:JNJ).  Integer has not quantified potential PFA contributions other than calling it a “tailwind.” BofA analysts expect some benefit to show up in 2H24 as more PFA devices are rolled ...